180 Life Sciences Corp. (KBLM) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17
	10-K	10-K	S-1	10-K	10-K	10-K
Revenues	0.0	0.0		0.0	0.0	0.0
Cost of goods sold	0.0	0.0		0.0	0.0	0.0
Gross profit	0.0	0.0		0.0	0.0	0.0
Selling, general and administrative [+]	15.5	11.7		1.2	0.6	0.3
General and administrative	15.5	11.7		1.2	0.6	0.3
Research and development	2.2	1.0
Other operating expenses	3.2	1.9
EBITDA [+]	-20.7	-14.5
EBITDA growth	43.5%			101.8%	74.2%
Depreciation		0.0
EBITA	-20.7	-14.4		-1.2	-0.6	-0.3
Amortization of intangibles	0.1	0.1
EBIT [+]	-20.8	-14.6		-1.2	-0.6	-0.3
EBIT growth	43.1%			101.8%	74.2%
Non-recurring items [+]	-2.9	1.1
Asset impairment	-3.3
Legal settlement	0.1	0.9
Interest income, net [+]				1.4	2.1	0.7
Interest expense	0.0	0.0
Interest income				1.4	2.1	0.7
Other income (expense), net [+]	-21.7	-4.7
Gain (loss) on debt retirement		0.0
Change in fair value of warrants	15.1	-4.7
Other		-0.1
Pre-tax income	-39.7	-20.3		0.2	1.5	0.3
Income taxes	-0.9	0.0		0.3	0.4	0.2
Tax rate	2.4%	0.1%		155.0%	28.4%	61.2%
Net income	-38.7	-20.3		-0.1	1.0	0.1

Basic EPS [+]	($20.38)	($12.96)		($0.02)	$0.25	$0.04
Growth	57.2%			-108.7%	595.7%
Diluted EPS [+]	($20.38)	($12.96)		($0.02)	$0.07	$0.01
Growth	57.2%			-130.9%	433.2%


Shares outstanding (basic) [+]	1.9	1.6		4.2	4.2	3.5
Growth	21.2%			1.3%	20.9%
Shares outstanding (diluted) [+]	1.9	1.6		4.2	14.9	9.4
Growth	21.2%			-71.6%	57.7%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.